Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Circulating tumour DNA in patients with hepatocellular carcinoma across tumour stages and treatments.

Gut - 7 Oct 2024

Campani Claudia, Imbeaud Sandrine, Couchy Gabrielle, Ziol Marianne, Hirsch Theo Z, Rebouissou Sandra, Noblet Bénédicte, Nahon Pierre, Hormigos Katia, Sidali Sabrina, Seror Olivier, Taly Valerie, Ganne Carrie Nathalie, Laurent-Puig Pierre, Zucman-Rossi Jessica, Nault Jean-Charles

Abstract excerpt

OBJECTIVE: Circulating tumour DNA (ctDNA) is a promising non-invasive biomarker in cancer. We aim to assess the dynamic of ctDNA in patients with hepatocellular carcinoma (HCC). DESIGN: We analysed 772 plasmas from 173 patients with HCC collected at the time of diagnosis or treatment (n=502), 24 hours after locoregional treatment (n=154) and during follow-up (n=116). For controls, 56 plasmas from patients with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to beta Catenin
Share to Carcinoma, Hepatocellular

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Circulating Tumor DNA

Share to Class I Phosphatidylinositol 3-Kinases

Share to Liver Neoplasms

Share to Neoplasm Staging

Share to NF-E2-Related Factor 2

Share to Telomerase

Source

Identifiers

PMID: 39054058
DOI: 10.1136/gutjnl-2024-331956

Genes

CTNNB1
NFE2L2
PIK3CA
TERT
TP53

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Circulating tumour DNA in patients with hepatocellular carcinoma across tumour stages and treatments.PMID 39054058Read ↗

Genetics of Hepatocellular Carcinoma: From Tumor to Circulating DNASemantic proximity Read ↗

Circulating tumor DNA as an emerging liquid biopsy biomarker for early diagnosis and therapeutic monitoring in hepatocellular carcinoma.Semantic proximity Read ↗

Circulating Tumor DNA and Hepatocellular CarcinomaSemantic proximity Read ↗

Circulating tumor DNA and its role in detection, prognosis and therapeutics of hepatocellular carcinomaSemantic proximity Read ↗

Circulating tumor DNA mutation analysis: advances in its application for early diagnosis of hepatocellular carcinoma and therapeutic efficacy monitoring.Semantic proximity Read ↗

Circulating-Free DNA Analysis in Hepatocellular Carcinoma: A Promising Strategy to Improve Patients’ Management and Therapy OutcomesSemantic proximity Read ↗

Noninvasive detection of tumor-associated mutations from circulating cell-free DNA in hepatocellular carcinoma patients by targeted deep sequencing.Semantic proximity Read ↗

Plasma Circulating Tumor DNA Sequencing Reveals the Landscape of Acquired Mutations in Patients with Hepatocellular Carcinoma: a Potential Predictive Value in Liquid BiopsySemantic proximity Read ↗

Circulating Cell-Free DNA in Hepatocellular Carcinoma: Current Insights and OutlookSemantic proximity Read ↗

Using cell-free DNA for HCC surveillance and prognosisSemantic proximity Read ↗

Next-Generation Sequencing of Circulating Tumor DNA Reveals Frequent Alterations in Advanced Hepatocellular CarcinomaSemantic proximity Read ↗

Circulating Tumor DNA Analysis for Liver Cancers and Its Usefulness as a Liquid BiopsySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.